WO2001011361A3 - Kit and method to assess the malignancy of neoplasias - Google Patents

Kit and method to assess the malignancy of neoplasias Download PDF

Info

Publication number
WO2001011361A3
WO2001011361A3 PCT/EP2000/007557 EP0007557W WO0111361A3 WO 2001011361 A3 WO2001011361 A3 WO 2001011361A3 EP 0007557 W EP0007557 W EP 0007557W WO 0111361 A3 WO0111361 A3 WO 0111361A3
Authority
WO
WIPO (PCT)
Prior art keywords
marker
antibodies
hormone
kit
protein
Prior art date
Application number
PCT/EP2000/007557
Other languages
French (fr)
Other versions
WO2001011361A2 (en
Inventor
Juergen A Frerichs
Original Assignee
Monotec Gmbh
Juergen A Frerichs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monotec Gmbh, Juergen A Frerichs filed Critical Monotec Gmbh
Priority to JP2001515966A priority Critical patent/JP2003506716A/en
Priority to EP00956391A priority patent/EP1240520A2/en
Priority to AU68353/00A priority patent/AU6835300A/en
Publication of WO2001011361A2 publication Critical patent/WO2001011361A2/en
Publication of WO2001011361A3 publication Critical patent/WO2001011361A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/723—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a diagnostic kit and use thereof for the stratification of patients for a treatment of hormone-dependent benign and malignant neoplasias. The kit contains antibodies that are directed against to a proliferation marker, preferably the Ki-67 protein, MCM, PCNA, Cyclines, phosphorylated histones, etc., and in particular the Ki-67 protein, on the one hand, and antibodies that are directed against a second marker selected form the group of hormone receptors such as the estrogen receptor, apoptotic marker like caspase cleaved cytokeratine 18 as defined by the mAb CD30, and bcl-2; transforming cell markers or tumor cell markers, like Her-2/neu on the other hand. The marker indices (e.g. Ki-67 marker index and hormone receptor status) generated with the aid of the antibodies can be set related to each other and serve for an optimal determination of the form of treatment.
PCT/EP2000/007557 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias WO2001011361A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2001515966A JP2003506716A (en) 1999-08-04 2000-08-03 Diagnostic kit and its use
EP00956391A EP1240520A2 (en) 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias
AU68353/00A AU6835300A (en) 1999-08-04 2000-08-03 Diagnostic kit and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE1999136618 DE19936618A1 (en) 1999-08-04 1999-08-04 Diagnostic kit and its use
DE19936618.7 1999-08-04

Publications (2)

Publication Number Publication Date
WO2001011361A2 WO2001011361A2 (en) 2001-02-15
WO2001011361A3 true WO2001011361A3 (en) 2001-11-15

Family

ID=7917102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007557 WO2001011361A2 (en) 1999-08-04 2000-08-03 Kit and method to assess the malignancy of neoplasias

Country Status (5)

Country Link
EP (1) EP1240520A2 (en)
JP (1) JP2003506716A (en)
AU (1) AU6835300A (en)
DE (1) DE19936618A1 (en)
WO (1) WO2001011361A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7361460B2 (en) 2003-04-11 2008-04-22 Digene Corporation Approach to molecular diagnosis of human papillomavirus-related diseases
WO2005033333A2 (en) * 2003-10-07 2005-04-14 Dako Denmark A/S Methods and compositions for the diagnosis of cancer
US8034549B2 (en) * 2006-02-09 2011-10-11 University Of South Florida Detection of cancer by elevated levels of BCL-2
US11199546B2 (en) 2014-01-22 2021-12-14 Koninklike Philips N.V. Stratification of patients for assessing the suitability of a therapy
ES2911415T3 (en) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Methods and kits
WO2016198833A2 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods
WO2019168085A1 (en) 2018-02-28 2019-09-06 日東紡績株式会社 Method for isolating cell nuclei having enhanced antigenicity from immobilized cells or ffpe tissue section, and antigen activator and kit therefor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312752A (en) * 1989-07-31 1994-05-17 Trustees Of Boston University Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins
EP0806668A2 (en) * 1996-05-10 1997-11-12 Becton, Dickinson and Company Method and kit for determining malignant potential in tissue cells
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
US6007996A (en) * 1995-12-12 1999-12-28 Applied Spectral Imaging Ltd. In situ method of analyzing cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744356A (en) * 1989-07-31 1998-04-28 Trustees Of Boston University Specific antibodies against an epitope existing within the A/B region of estrogen receptor proteins
WO1997016731A1 (en) * 1995-11-02 1997-05-09 Thomas Jefferson University Immunocytochemical staining of exfoliated cervical samples

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5312752A (en) * 1989-07-31 1994-05-17 Trustees Of Boston University Specific antibodies against the DNA-binding domain of and immunoassays to determine the presence and functional status of estrogen receptor proteins
US6007996A (en) * 1995-12-12 1999-12-28 Applied Spectral Imaging Ltd. In situ method of analyzing cells
EP0806668A2 (en) * 1996-05-10 1997-11-12 Becton, Dickinson and Company Method and kit for determining malignant potential in tissue cells
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DELLAS ATHANASSIOS ET AL: "Investigation of the Bcl-2 and C-myc expression in relationship to the Ki-67 labelling index in cervical intraepithelial neoplasia.", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, vol. 16, no. 3, 1997, pages 212 - 218, XP000980205, ISSN: 0277-1691 *
SACCANI JOTTI G ET AL: "PRELIMINARY STUDY ON ONCOGENE PRODUCT IMMUNOHISTOCHEMISTRY C-ERBB-2 C-MYC RAS P21 EGFR IN BREAST PATHOLOGY", INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, vol. 7, no. 1, 1992, pages 35 - 42, XP000980522, ISSN: 0393-6155 *
See also references of EP1240520A2 *

Also Published As

Publication number Publication date
WO2001011361A2 (en) 2001-02-15
AU6835300A (en) 2001-03-05
JP2003506716A (en) 2003-02-18
EP1240520A2 (en) 2002-09-18
DE19936618A1 (en) 2001-03-15

Similar Documents

Publication Publication Date Title
WO2004058171A3 (en) Antibodies against gpr64 and uses thereof
AU7689496A (en) Design of hormone-like antibodies with agonistic and antagonistic functions
PT1157041E (en) ANTIBODIES FOR CANCER THERAPY AND DIAGNOSIS
WO2001098357A3 (en) Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
IL156618A0 (en) Crystals of whole antibodies and fragments thereof, methods for the preparation thereof and diagnostic kits utilizing the same
WO1998058052A3 (en) Disease associated protein kinases
EP0753072A1 (en) Biological markers of benign prostate hyperplasia
WO2001025791A3 (en) Prostate cancer marker proteins
EP2251695A3 (en) Markers associated with endometrial disease
WO2001011361A3 (en) Kit and method to assess the malignancy of neoplasias
ATE292468T1 (en) USE OF BIOGENIC ESTROGEN SULFAMATES FOR HORMONE SUBSTITUTION THERAPY
EP1433792A3 (en) Human receptor proteins, related reagents and methods
AU1233701A (en) Methods and compositions for treating atheroma, tumors and other neoplastic tissue
WO1997048804A3 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
WO2002058538A3 (en) Methods of imaging and targeting vasculature
WO2001057219A3 (en) Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
CA2435320A1 (en) Compositions and methods for the use of fibronectin fragments in the diagnosis of cancer
AU2001233917A1 (en) Bcmp-7 as marker for diagnosis of breast cancer
WO2002023200A3 (en) Human breast cancer biomarkers
WO2004083241A3 (en) Btc-interacting proteins and use thereof
Davio et al. H 1 and H 2 histamine receptors in human mammary carcinomas
EP1512755A3 (en) Markers for prostate cancer
EP0773026A3 (en) NK-1 receptor antagonists for the treatment of cancer
WO2000039154A3 (en) Peptides of the at1 receptor and their use for preeclampsia and malign hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2000956391

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10048910

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2000956391

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 2000956391

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000956391

Country of ref document: EP